Anheuser-Busch InBev (NYSE: BUD) dropped what would have been the biggest initial public offering (IPO) of 2019 last Friday.
But don’t be fooled – even though the $9.8 billion IPO on the Hong Kong exchange fell through, AB InBev stock is still a major breakout candidate.
The company blamed “prevailing market conditions” for the suspension of its bid to list on the Hong Kong Stock Exchange (HKE) – which was even greater than Uber’s $8.1 billion in May.
The Hong Kong IPO was supposed to fuel expansion in China with its Asian subsidiary, Budweiser Brewing Co. APAC Ltd.
Bloomberg cites BUD’s growing competition in the region. Craft beverages are out-trending traditional beer in China, and competitor Heineken NV (NYSE: HEINY) just struck a deal with China Resources Beer, a state-owned brewer.
AB executives saw the millions of drinkers they serve in China and believed an IPO would reinforce growth. And considering this IPO would bring HKE significantly closer to leading the worldwide IPO market, company bankers agreed it made sense.
This, and the AB stock‘s success on the New York Stock Exchange, led it to push its high target up from $6 billion to $10 billion before the IPO date.
So it appears AB InBev may have overestimated institutional demand in Hong Kong and demand for Budweiser in China.
It was too little, too late when it offered to price shares at the lower end of the HK$40 to HK$47 range. Funds were threatening to pull out hours before the IPO, and Anheuser-Bush InBev was forced to call it off.
You Have to See This to Believe It: America’s favorite “shark” debuts the Angels & Entrepreneurs Summit. Watch now…
An immediate 3% drop in AB InBev stock followed the announcement.
And from reading the above, most would think Budweiser was running off with a tail between its legs.
But on Monday, BUD stock started rising again. In fact, it recovered completely… and more.
From its low of $85.42 on July 12 (Friday), the stock climbed up to $88.72 in less than a week’s time – a 3.8% jump.
Those sound like meager gains, but when you consider the AB InBev stock is up 32% since the start of 2019 – beating the S&P 500 – you start to get a different story…
And when you see analysts projecting 16.5% more growth for the year, for total growth of 48.5%, you get a little more hopeful…
But when you see the ace BUD has up its sleeve… you become a full-fledged optimist.
You see, there are two ways to look at a failed IPO. One is that the company overestimated institutional demand.
“Option B” is that institutional investors are underestimating the company.
Today, we’ll show you why the answer is option B – and why that means a big opportunity for you.
It’s not just the analyst projections of 70% gains this year, and it’s not just the perfect Money Morning Stock VQScore™ of 4.15 telling us BUD is poised for breakout gains.
The Ace Driving Up AB InBev Stock
Anheuser-Bush InBev is still the world’s largest brewer.
But a recent investment could still take the company sky-high in the coming years.
Last December, AB partnered with cannabis giant Tilray Inc. (NYSE: TLRY) for a $100 million joint venture to research cannabis-infused, non-alcoholic beverages in Canada.
The move was supported by figures suggesting alcohol consumption and smoking where on the decline. Last year, the World Health Organization (WHO) said the number of people consuming alcohol had shrunk by 5% since the year 2000.
It’s also supported by the fact that Canada legalized weed on a federal level in 2018.
And though the AB InBev-Tilray partnership is meant for Canada, it’s only a matter of time before the United States adopts the same trend. Eleven states, along with Washington, D.C., have legalized recreational marijuana today. Seven have decriminalized it in the last two years.
A study done by Gallup said 64% of Americans favored legalization in 2018.
So today we’re seeing major trends toward medicinal applications of marijuana and cannabis legalization altogether.
The cannabidiol (CBD) industry (cannabis’ non-hallucinogenic cousin hemp) is another target for AB and Tilray to infuse beverages.
Brightfield predicts the CBD industry will see growth from its 2018 sales of $591 million to $22 billion in 2022. That’s growth of 3,622% in just four years, and AB InBev is going to get a piece of that.
You can see it riding the wave before your very eyes. Anheuser-Busch stock sells for $88.73 right now, but it’s projected to break $113 by the end of the year. That’s a nearly 70% gain.
Management has pledged to take their debt below a net debt-to-EBITDA ratio of 4 by the end of 2020. And AB’s high free cash flows actually make this feasible, according to Barclays, which points to its high free cash flow of $6.95 billion at the end of 2018.
AB’s net profit also jumped 31% to $1.4 billion in 2018 from a year earlier. Revenue climbed by 8.6% to $8.5 billion.
With this company’s top VQScore, cash on hand, and catalysts on the way, expect it to soar in no time.
Anyone Can Become an Angel Investor with as Little as $50
Angel investing used to be off limits to the average American… but Shark Tank’s Robert Herjavec said it best during this live broadcast: “The walls have finally come down. You no longer have to be rich, famous, or powerful to become an angel investor!”
Congress has now made it possible for you to take advantage of these life-changing deals.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2019 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.